Abeona Therapeutics (NASDAQ:ABEO) Raised to Hold at StockNews.com

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a report released on Thursday morning.

A number of other research analysts have also recently issued reports on ABEO. Cantor Fitzgerald restated an “overweight” rating and set a $18.00 price objective on shares of Abeona Therapeutics in a report on Tuesday, October 29th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a report on Monday.

Abeona Therapeutics Stock Up 6.3 %

Shares of NASDAQ ABEO opened at $6.41 on Thursday. The stock has a market cap of $278.64 million, a P/E ratio of -2.38 and a beta of 1.52. The firm has a 50 day moving average price of $6.24 and a 200 day moving average price of $5.32. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $9.01.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new position in Abeona Therapeutics during the third quarter worth $84,000. Charles Schwab Investment Management Inc. acquired a new position in Abeona Therapeutics during the third quarter worth $151,000. XTX Topco Ltd acquired a new position in Abeona Therapeutics during the third quarter worth $160,000. Bank of New York Mellon Corp boosted its holdings in Abeona Therapeutics by 2.0% during the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock worth $515,000 after purchasing an additional 2,434 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its holdings in Abeona Therapeutics by 54.3% during the third quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock worth $607,000 after purchasing an additional 33,831 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.